NeOnc Technologies develops drug candidates for brain cancers, including NEO100 and NEO212, which are still in clinical trials. It last closed at $4.33 on Nov 17, down 4.63% on the day. The average 12-month price target from 2 analysts is $17.50 (+304.2% from the last close), with a high of $20.00 and a low of $15.00.
Only 2 firms rated NTHI in the past 90 days, not enough for a consensus
Average 12-month target
$17.50
▲ 304.2% upside
Based on 2 analysts who set a price target on NTHI in the past 90 days. The average target is $17.50, with a high of $20.00 and a low of $15.00, compared with the last close of $4.33.
Low $15.00Avg $17.50High $20.00
Blue marker: last close $4.33
Highest target$20.00
Average target$17.50
Lowest target$15.00
Latest rating changes
Roth CapitalInitiated
Sep 24Buy$20
BTIGReiterated
Sep 8Buy$15
Alliance Global PartnersInitiated
May 19Buy$13
Maxim GroupInitiated
May 18Buy$20
BTIGInitiated
Apr 24Buy$15
Date
Firm
Action
Rating
Price target
Sep 24
Roth Capital
Initiated
Buy
$20
Sep 8
BTIG
Reiterated
Buy
$15
May 19
Alliance Global Partners
Initiated
Buy
$13
May 18
Maxim Group
Initiated
Buy
$20
Apr 24
BTIG
Initiated
Buy
$15
Loading…
Technical Analysis
NTHI · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, nearing overbought
The stock is 17% above its 20 day and 24% above its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 63), near overbought. The nearest support is the swing low (Jun 9) at $4.24, and the nearest resistance the Pivot at $4.52.
Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityHigh, 11.2%/day
Key levels
$11.3852 week high+162.8%
$5.17200 day average+19.4%
$4.74Pivot R1+9.5%
$4.54Swing high (Jul 7)+4.8%
$4.52Pivot+4.4%
$4.33Last close
$4.24Swing low (Jun 9)−2.1%
$4.10Pivot S1−5.3%
$3.70100 day average−14.5%
$3.5820 day average−17.3%
$3.2950 day average−24.0%
$2.5052 week low−42.3%
Indicators
RSI (14)
62.74
Strong, overbought above 70
Neutral
MACD
0.40
Above its signal line
Bullish
Stochastic
67.2
Middle of its range
Neutral
ADX (14)
40.3
Strong uptrend
Williams %R
-43.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
94.9
Oversold below −100, overbought above 100
Neutral
Rate of change
+41.0%
Change over 10 sessions
Bullish
ATR (14)
$0.48
Typical daily range, 11.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumImproving
StretchNormal
VolatilityNormal, 24.0%/day
Key levels
$11.3852 week high+162.8%
$5.17200 day average+19.4%
$4.74Pivot R1+9.5%
$4.54Swing high (Jul 7)+4.8%
$4.52Pivot+4.4%
$4.33Last close
$4.24Swing low (Jun 9)−2.1%
$4.10Pivot S1−5.3%
$3.70100 day average−14.5%
$3.5820 day average−17.3%
$3.2950 day average−24.0%
$2.5052 week low−42.3%
Indicators
RSI (14)
50.13
Middle of its range
Neutral
MACD
-0.45
Above its signal line
Bullish
Stochastic
52.5
Middle of its range
Neutral
ADX (14)
15.5
No clear trend
Williams %R
-44.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
100.2
Oversold below −100, overbought above 100
Overbought
Rate of change
+17.7%
Change over 10 sessions
Bullish
ATR (14)
$1.04
Typical daily range, 24.0% of price
MA 10Above
MA 20Above
MA 50Below
MA 100–
MA 200–
What happened before, for NTHI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NTHI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in NTHI in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTHI is in one of them and how their past NTHI trades turned out.
NeOnc Technologies develops drugs for cancers that start in the brain or spread there, including glioblastoma, meningioma and brain metastases from lung, breast and skin cancers. Its lead candidates are NEO100, a purified form of perillyl alcohol given by nasal spray, and NEO212, an oral drug that combines temozolomide with perillyl alcohol. The company has no approved products yet and is testing its candidates in trials with patients who have brain tumors. It is based in Calabasas, California.